Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

Bearish flow noted in AstraZeneca (AZN) with 1,547 puts trading, or 1.9x expected. Most active are 2/14 weekly 68 puts and Feb-25 70 puts, with ...

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects. Volunteers aged ...